Czech Health Minister David Rath is to launch a new and controversial medicines directive to come into force on August 1. Dr Rath has said that the new regulations will achieve savings of around $90.0 million a year within the health insurance sector.
Doctors will be able to increase spending on drugs and medicines by this amount without breaching health fund spending limits. However, pharmaceutical companies delivering products to the Czech market, say the new regulation will restrict patient access to medicines and increase patient charges, a claim Dr Rath rejects.
The Ministry of Health has reportedly reached agreement with a number of drugmakers on a price reduction for more expensive drugs and the original draft regulation has been modified so that patient charges for anti-depressant and cardiovascular drugs will not increase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze